glutathione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1312 | 70-18-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 65.76 | 22.52 | 27 | 1523 | 37115 | 63450357 |
| Drug-induced liver injury | 44.43 | 22.52 | 21 | 1529 | 40201 | 63447271 |
| Eosinophilic pneumonia chronic | 36.76 | 22.52 | 6 | 1544 | 192 | 63487280 |
| Bowel movement irregularity | 25.20 | 22.52 | 8 | 1542 | 5256 | 63482216 |
| Chronic disease | 23.64 | 22.52 | 4 | 1546 | 160 | 63487312 |
| Defaecation urgency | 22.72 | 22.52 | 7 | 1543 | 4168 | 63483304 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 74.95 | 28.94 | 35 | 1229 | 44328 | 34911339 |
| Lymphocyte count decreased | 58.13 | 28.94 | 24 | 1240 | 22598 | 34933069 |
| Neutrophil count increased | 53.76 | 28.94 | 21 | 1243 | 17125 | 34938542 |
| Incision site pain | 50.48 | 28.94 | 12 | 1252 | 1826 | 34953841 |
| Platelet count decreased | 49.33 | 28.94 | 38 | 1226 | 119679 | 34835988 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 126.78 | 24.96 | 57 | 2549 | 73050 | 79668732 |
| Incision site pain | 71.79 | 24.96 | 17 | 2589 | 2813 | 79738969 |
| Platelet count decreased | 68.29 | 24.96 | 54 | 2552 | 194610 | 79547172 |
| Lymphocyte count decreased | 66.70 | 24.96 | 32 | 2574 | 47257 | 79694525 |
| Drug-induced liver injury | 64.84 | 24.96 | 35 | 2571 | 66082 | 79675700 |
| Neutrophil count increased | 60.84 | 24.96 | 26 | 2580 | 29370 | 79712412 |
| Alanine aminotransferase increased | 38.38 | 24.96 | 36 | 2570 | 162534 | 79579248 |
| Red blood cells urine positive | 35.57 | 24.96 | 11 | 2595 | 4952 | 79736830 |
| White blood cell count increased | 31.13 | 24.96 | 23 | 2583 | 74610 | 79667172 |
| Blood albumin decreased | 29.95 | 24.96 | 15 | 2591 | 24228 | 79717554 |
| Eosinophilic pneumonia chronic | 29.25 | 24.96 | 6 | 2600 | 512 | 79741270 |
| White blood cell count decreased | 27.04 | 24.96 | 32 | 2574 | 188256 | 79553526 |
| Bone marrow failure | 26.52 | 24.96 | 18 | 2588 | 51089 | 79690693 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V03AB32 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
| CHEBI has role | CHEBI:22586 | antioxidants |
| CHEBI has role | CHEBI:23357 | cofactor |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
| CHEBI has role | CHEBI:85046 | skin lightening agents |
| CHEBI has role | CHEBI:176497 | geroprotectors |
| CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.97 | acidic |
| pKa2 | 3.3 | acidic |
| pKa3 | 9.09 | acidic |
| pKa4 | 11.82 | acidic |
| pKa5 | 13.85 | acidic |
| pKa6 | 9.79 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glutathione S-transferase kappa 1 | Enzyme | IC50 | 7.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020562 | VUID |
| N0000148266 | NUI |
| D00014 | KEGG_DRUG |
| 4020562 | VANDF |
| C0017817 | UMLSCUI |
| CHEBI:16856 | CHEBI |
| 0P0 | PDB_CHEM_ID |
| CHEMBL1543 | ChEMBL_ID |
| DB00143 | DRUGBANK_ID |
| D005978 | MESH_DESCRIPTOR_UI |
| 124886 | PUBCHEM_CID |
| 6737 | IUPHAR_LIGAND_ID |
| GAN16C9B8O | UNII |
| 4890 | RXNORM |
| NOCODE | MMSL |
| 003447 | NDDF |
| 423272009 | SNOMEDCT_US |
| 55477000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Bio-7 Serum | HUMAN OTC DRUG LABEL | 2 | 71583-1002 | LIQUID | 3 g | TOPICAL | unapproved drug other | 7 sections |
| Bio-7 | HUMAN OTC DRUG LABEL | 2 | 71583-1003 | CREAM | 3.26 g | TOPICAL | unapproved drug other | 7 sections |
| HARUTO HANGOVER DEFENCEPATCH | HUMAN OTC DRUG LABEL | 1 | 80094-0001 | PATCH | 1.42 mg | TOPICAL | unapproved drug other | 7 sections |
| Deyanling(Cranberry Flavored Collagen Peptide) | HUMAN OTC DRUG LABEL | 3 | 82570-004 | POWDER | 5 g | TOPICAL | unapproved drug other | 8 sections |